Valsacor is an angiotensin II receptor antagonist.
Release form and composition
Valsakor tablets are made containing the active ingredient valsartan in the amount of 40, 80 or 160 mg.
In blister packs of 7, 10 or 14 tablets.
Indications for use
According to the instructions, Valsakor is prescribed for:
- High blood pressure;
- Chronic heart failure as part of complex therapy, as well as for patients not receiving ACE inhibitors.
Valsakor is prescribed to reduce cardiovascular mortality in stable patients who have dysfunction or insufficiency of the left ventricle after myocardial infarction.
According to the instructions, Valsakor is contraindicated in the following cases:
- During pregnancy and breastfeeding;
- Age up to 18 years;
- Lactose intolerance, galactose or glucose absorption disorder syndrome, galactosemia;
- Individual intolerance to valsartan or auxiliary components of the drug.
When using Valsakor, care should be taken when:
- Low blood pressure;
- Renal and / or liver failure;
- Bilateral renal artery stenosis or single kidney artery stenosis;
- Low salt diet;
- Conditions associated with a decrease in BCC (vomiting, diarrhea).
Dosing and Administration
Valsakor is indicated for internal use, regardless of the meal.
With elevated blood pressure, Valsacor is prescribed at a dose of 80 mg once a day. The antihypertensive effect of the drug develops over 10–15 days and reaches a maximum 4 weeks after the start of therapy. The maximum daily dose of the drug is 320 mg. The combination of the drug with other antihypertensive drugs is allowed.
In chronic heart failure, the recommended initial dose of Valsakor is 40 mg twice a day. With good tolerance, the dose of the drug gradually increases first to 80 mg, and then to 160 mg twice a day.
If patients take diuretics simultaneously with Valsakor, it is recommended to monitor kidney function and blood pressure.
The use of Valsakor after myocardial infarction should be started within 12 hours after the attack. The initial dose is 20 mg twice a day with a gradual increase to 40, 80 and 160 mg twice a day for several weeks.
The use of Valsakor may cause the following side effects from various systems of vital activity of the organism:
- Central and peripheral nervous systems: headache, vertigo, dizziness, fainting, insomnia;
- Respiratory system: pharyngitis, sinusitis, cough, rhinitis, infections of the upper respiratory tract;
- Cardiovascular system: severe arterial hypotension, heart failure;
- Musculoskeletal system: myalgia, back pain, arthralgia;
- The digestive system: abdominal pain, diarrhea, nausea;
- Urinary system: renal dysfunction;
- Laboratory indicators: decrease in hematocrit and hemoglobin, hyperkalemia, neutropenia, hypercreatininemia, increased activity of liver enzymes, thrombocytopenia, hyperbilirubinemia;
- Reproductive system: decreased libido;
- Allergies: skin rash, angioedema, hypersensitivity reactions (vasculitis, serum sickness), pruritus;
- Other side effects of Valsakor: fatigue, weakness, asthenia, edema.
In the case of prolonged use of Valsakor in high doses, overdose may develop, accompanied by a pronounced decrease in blood pressure, which can lead to shock or collapse.
Symptomatic overdose treatment. The patient is recommended to induce vomiting and flush the stomach. In case of arterial hypotension, sodium chloride solution is administered to 0.9%.
No clinically significant drug interaction of Valsakor with other drugs has been identified.
The combined use of valsartan with potassium-sparing diuretics and nutritional supplements can cause hyperkalemia and an increase in the hypotensive effect, so care should be taken.
During pregnancy, valsartan is contraindicated, especially in the second and third trimesters. If pregnancy is established, valsartan therapy should be promptly discontinued.
If it becomes necessary to use the drug during lactation, it is necessary to solve the issue of stopping breastfeeding.
Valsacor therapy in patients with heart failure, as a rule, causes a decrease in blood pressure, however, with constant medical supervision and dose adjustment, it is not necessary to discontinue medication. Also, some patients may experience a change in renal function.
Allowed the appointment of the drug in conjunction with other drugs that are usually indicated for use after myocardial infarction: acetylsalicylic acid, satin, thrombolytic, beta-blockers.
If the patient has a deficiency of sodium in the body, it is recommended to restore electrolyte balance before starting treatment with Valsakor.
In case of impaired renal function, dose adjustment is not required. In obstructive diseases of the biliary tract, Valsacor should be prescribed with caution.
During drug treatment patients should be careful in the management of potentially dangerous mechanisms that require high concentration of attention.
Structural analogues of Valsakor are the following drugs:
Terms and conditions of storage
According to the instructions, Valsakor should be stored in a dark, dry, protected from children place. The shelf life of the drug is 3 years.